文献速递其他结缔组织病

尼达尼布在系统性硬化症相关间质性肺病中的安全性与耐受性:SENSCIS试验数据

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
PubMed 文献 · Ann Rheum Dis · 2020-08-05

SENSCIS试验纳入576例系统性硬化症相关间质性肺病(SSc-ILD)患者,随机接受尼达尼布150mg每日两次或安慰剂,评估52周内不良事件及剂量调整。尼达尼布组腹泻发生率75.7%,因腹泻永久停药6.9%;48.3%患者至少一次减量或中断治疗,不良事件导致永久停药16.0%。尼达尼布不良事件谱与特发性肺纤维化中已知安全性一致,剂量调整有助于患者维持治疗。

要点

  • 尼达尼布组腹泻发生率75.7%,显著高于安慰剂组31.6%。
  • 尼达尼布组48.3%患者需减量或中断治疗,16.0%因不良事件永久停药。
  • 剂量调整不影响尼达尼布组用力肺活量下降速率。

核心结论

  • 尼达尼布在SSc-ILD患者中的不良事件谱与特发性肺纤维化中已知安全性一致。
  • 剂量调整对减少不良事件影响、帮助患者维持治疗很重要。

研究设计与样本

  • SENSCIS试验将SSc-ILD患者随机分配至尼达尼布150mg每日两次组(n=288)或安慰剂组(n=288)。
  • 通过中断治疗或减量至100mg每日两次管理不良事件,评估52周内不良事件和剂量调整。

主要发现

  • 尼达尼布组和安慰剂组腹泻发生率分别为75.7%和31.6%。
  • 腹泻导致永久停药的比例在尼达尼布组和安慰剂组分别为6.9%和0.3%。
  • 尼达尼布组和安慰剂组分别有48.3%和12.2%患者至少一次减量和/或中断治疗。
  • 不良事件导致永久停药的比例在尼达尼布组和安慰剂组分别为16.0%和8.7%。
  • 尼达尼布相关不良事件在年龄、性别、种族和体重亚组中相似。

关键数值与推荐

  • 尼达尼布组腹泻发生率75.7%,安慰剂组31.6%。
  • 尼达尼布组因腹泻永久停药6.9%,安慰剂组0.3%。
  • 尼达尼布组48.3%患者至少一次减量或中断治疗,安慰剂组12.2%。
  • 尼达尼布组不良事件导致永久停药16.0%,安慰剂组8.7%。

临床怎么用

  • 临床使用尼达尼布治疗SSc-ILD时,应通过剂量调整管理不良事件以帮助患者维持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomised to receive nintedanib 150 mg two times per day or placebo. To manage adverse events, treatment could be interrupted or the dose reduced to 100 mg two times per day. We assessed adverse events and dose adjustments over 52 weeks. RESULTS: A total of 576 patients received nintedanib (n=288) or placebo (n=288). The most common adverse event was diarrhoea, reported in 75.7% of patients in the nintedanib group and 31.6% in the placebo group; diarrhoea led to permanent treatment discontinuation in 6.9% and 0.3% of patients in the nintedanib and placebo groups, respectively. In the nintedanib and placebo groups, respectively, 48.3% and 12.2% of patients had ≥1 dose reduction and/or treatment interruption, and adverse events led to permanent discontinuation of the trial drug in 16.0% and 8.7% of patients. The adverse events associated with nintedanib were similar across subgroups defined by age, sex, race and weight. The rate of decline in forced vital capacity in patients treated with nintedanib was similar irrespective of dose adjustments. CONCLUSIONS: The adverse event profile of nintedanib in patients with SSc-ILD is consistent with its established safety and tolerability profile in patients with idiopathic pulmonary fibrosis. Dose adjustment is important to minimise the impact of adverse events and help patients remain on therapy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Ann Rheum Dis. 2020. PMID: 32759258. doi:10.1136/annrheumdis-2020-217331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。